Homepage > Company > Media > Pharma News > 2021 > SK Bioscience, GSK Launch Phase 3 Trial for COVID-19 Vaccine

SK Bioscience, GSK Launch Phase 3 Trial for COVID-19 Vaccine

GlaxoSmithKline (GSK) and SK Bioscience have begun a phase 3 study of SK’s COVID-19 vaccine candidate, GBP510, in combination with GSK’s adjuvant.

The global late-stage study will enroll approximately 4,000 volunteers to compare GBP510, which is a nanoparticle vaccine, with AstraZeneca’s adenovirus-based COVID-19 vaccine. Results from the trial are expected during the first half of 2022.

If the vaccine is approved, the shot is expected to be shipped worldwide via the World Health Organization-backed COVAX vaccine-sharing program, the companies said.

September 2, 2021

https://www.fdanews.com/

Read also

Phase II Success for Parkinson’s Stem Cell Therapy

Hope Biosciences reports significant motor function gains in Parkinson’s Phase II trial for HB-adMSC stem cell therapy.

FDA Approves Mitapivat for Alpha and Beta Thalassemia Anemia

FDA grants approval for Mitapivat (Aqvesme) to treat anemia in adults with alpha- or beta-thalassemia. Explore clinical data.

Radiopharmaceuticals & Advanced Preclinical Models: Bridging Discovery to Clinic | ChemDiv

Explore how patient-derived xenografts (PDX) and radiolabeled compounds are transforming radiopharmaceutical development, offering unparalleled insight into tumor biology for precision oncolog...

Ipsen & Simcere: $1 Billion Breakthrough in LRRC15-Targeting ADC Development

Ipsen acquires global rights to SIM0613, a preclinical LRRC15-targeting ADC from Simcere Zaiming. Learn about this $1.06B deal and the future of oncology therapeutics.